StockNews.AI
SSKN
StockNews.AI
151 days

STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update

1. SSKN will report Q4 2024 results on March 27, 2025. 2. Management will discuss results and corporate developments in a conference call. 3. STRATA's products target dermatologic conditions like psoriasis and acne. 4. A unique partnership program aids in marketing and service support for products. 5. Forward-looking statements indicate uncertainty in financial projections.

Earnings
+2.04%Current Return
VS
+1.68%S&P 500
$2.5503/21 01:49 PM EDTEvent Start
$2.60203/24 02:01 PM EDTLatest Updated
6m saved
Insight
Article

FAQ

Why Bullish?

The upcoming earnings report could potentially reveal positive financial performance, similar to past quarters.

How important is it?

Q4 earnings can influence sentiment and investment decisions, impacting stock performance.

Why Short Term?

Immediate effects expected post-earnings report; longer-term effects depend on ongoing performance.

Related Companies

AXNXHGENMMSI
HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Thursday, March 27, 2025 to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session. To listen to the conference call, interested parties within the U.S. should dial 1-844-481-2523 (domestic) or 1-412-317-0552 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the STRATA Skin Sciences, Inc. conference call. The conference call will also be available through a live webcast that can be accessed at STRATA Skin Sciences YE24 Earnings Webcast. A telephonic replay of the call will be available until April 3, 2025 by dialing 1-877-344-7529 (or 1-412-317-0088 for international toll callers) and using replay access code 8210574. To access the replay using an international dial-in number, please see here. A webcast earnings call replay will be available approximately one hour after the live call and remain accessible until September 21, 2025. About STRATA Skin Sciences, Inc.STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System. STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice. Safe HarborThis press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com. Investor Contact:CORE IR516-222-2560IR@strataskin.com

Related News